12.06.16
Dr. Joseph Reo has been appointed director of Global Scientific Affairs at Catalent Pharma Solutions. Dr. Reo will be responsible for internal scientific affairs to evolve the company’s scientific offerings, including generation of scientific content, integration of scientific communications, managing industry, private and academic relationships, and serving as co-chair of the Catalent Applied Drug Delivery Institute. He will also lead Catalent’s competitive technical intelligence function, its assessment of new growth opportunities, and early-phase development of new technology platforms through collaboration with the Institute.
Dr. Reo has more than 35 years of experience in the pharmaceutical industry, specializing in modified release technologies, polymer engineering and science, solids, liquids, semi-solids, nasal delivery, and the switch from prescription to OTC medications.
He joins the company from Bayer HealthCare, where he was director, Rx-to-OTC Switch Science, and was responsible for leading the science disciplines and project team for the development of prescription to non-prescription classification change. Prior to this, Dr. Reo worked in Rx-to-OTC roles both at Bayer, and previously, with Merck Consumer Healthcare.
“We welcome Joe to Catalent in his new role, leading our scientific affairs team,” said Julien Meissonnier, vice president Science and Technology. “His proven expertise in drug delivery and experience in scientific partnerships will certainly be an asset to continue Catalent’s strategy of engaging with the external scientific community. Joe will play a key role in enhancing and evolving Catalent’s scientific offerings to deliver better outcomes to patients.”
Dr. Reo has more than 35 years of experience in the pharmaceutical industry, specializing in modified release technologies, polymer engineering and science, solids, liquids, semi-solids, nasal delivery, and the switch from prescription to OTC medications.
He joins the company from Bayer HealthCare, where he was director, Rx-to-OTC Switch Science, and was responsible for leading the science disciplines and project team for the development of prescription to non-prescription classification change. Prior to this, Dr. Reo worked in Rx-to-OTC roles both at Bayer, and previously, with Merck Consumer Healthcare.
“We welcome Joe to Catalent in his new role, leading our scientific affairs team,” said Julien Meissonnier, vice president Science and Technology. “His proven expertise in drug delivery and experience in scientific partnerships will certainly be an asset to continue Catalent’s strategy of engaging with the external scientific community. Joe will play a key role in enhancing and evolving Catalent’s scientific offerings to deliver better outcomes to patients.”